Introduction
Covalent attachment of isoprenoid lipids is now recognized as an important modification of many proteins involved in cellular signalling [ 1, 2] . This type of modification, termed prenylation, involves attachment of either the 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoid to C-terminal cysteine residues of proteins. Known prenylated proteins include a number of GTP-binding regulatory proteins (G proteins); these proteins are responsible for controlling a wide spectrum of signal-transduction pathways [ 2, 3] . Recent evidence indicates that prenylation imparts properties to these proteins that both promote their membrane interactions and influence their biological activities ~2~41.
Enzymology of protein prenylation
The rus oncogene products comprise a particular class of G proteins which has attracted significant attention to the field of protein prenylation. Ras proteins are farnesylated, and the modification is required for oncogenic forms of these proteins to transform cells [5, 6] . The discovery of the farnesyl modification of the Ras proteins led to the development of the first in vitro system to analyse protein prenylation. A cytosolic enzyme was identified which could catalyse the addition of a farnesyl group to Ras produced via bacterial expression. Purification of this enzyme, termed protein farnesyltransferase (FTase), revealed it to comprise two polypeptides of 48 kDa (designated the a subunit) and 46kDa (B subunit) [7] . A surprising property of FTase was that the enzyme was capable of recognizing short peptides which contained the CaaX sequence (the C-terminal motif which directs prenylation) of known farnesylated proteins [7] . Simple tetrapeptides comprised of just this sequence were found to bind to the enzyme with aftinity equal to that of the parental protein from which they were derived. A subset of these tetrapeptides could not serve as substrates for the enzyme; instead they were true competitive inhibi- tors of the reaction [8] . This property has been exploited in the design of peptidomimetic compounds which are cell-permeable, specific inhibitors of FTase. Treatment of Ras-transformed cells with these compounds results in reversion of the transformed phenotype, indicating that FTase may indeed be a good target for anti-cancer therapeutics [9, 10] . The widespread prevalence of mutated rus alleles in human cancers (approx. 25% of all cancers, and approx. 90% of pancreatic cancers, for example) makes the development of inhibitors to this protein an important area of cancer research An intriguing trend that became apparent during early studies identifying isoprenoids attached to distinct prenylated proteins was that proteins containing methionine or serine at their C-termini were farnesylated, while those ending in leucine were modified by geranylgeranyl [ 11. These and other observations suggested the existence of a distinct enzyme which would catalyse the addition of geranylgeranyl to certain proteins in the CaaX class. Using an approach similar to that which led to the identification of FTase, an enzymic activity capable of transferring the geranylgeranyl group from geranylgeranyl diphosphate to candidate proteins was identified [12] [13] [14] . This enzyme, termed protein geranylgeranyltransferase type I (GGTase-I), exhibits properties similar to those of FTase, including the ability to recognize peptides containing the CaaX motif of known geranylgeranylated proteins [ 12, 131. The C-terminal leucine residue was shown to be responsible for the specific recognition of substrate proteins by GGTase-I by reproducing a Ras protein with a leucine-for-serine switch at the C-terminal position, converting the Ras protein from an FTase into a GGTase-I substrate [ 121.
Mammalian FTase and GGTase-I share many properties. Both proteins are zinc metalloenzymes with similar kinetic mechanisms [15] [16] [17] [18] . Both enzymes are heterodimers which contain a common subunit (the a subunit) of 48 kDa and distinct / 3 subunits of 46kDa (FTase) and 43kDa (GGTase-I) [7, 19] . R a s e [20, 21] and GGTase-I [22] have been cloned and sequence analysis confirmed that the a subunits are the products of the same gene and revealed that the /3 subunits have [111.
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approx. 35% sequence identity at the amino acid level. The significance of a common subunit for the two enzymes is not yet clear, but the existence of an identical a subunit and a highly homologous /3 subunit for these two protein prenyltransferases suggests that discrete segment(s) of the / 3 subunit are responsible for the remarkable protein substrate specificities of the enzymes.
It was noted early on that post-translational modifications in addition to prenylation are performed on proteins containing the CaaX motif. In particular, the mature forms of most (but apparently not all [23] ) of these proteins are missing the three C-terminal residues (i.e. the 'aaX). A cellular peptidase has been identified which removes these amino acids from the prenylated protein [24, 25] . In contrast with the protein prenyltransferases, the protease involved in this processing is membraneassociated. Subcellular fractionation studies have identified the protease activity in the microsomal compartment of cells, suggesting that newly prenylated proteins are targeted initially to some intracellular membrane compartment for furtherprocessing (see below). Following this proteolytic reaction, the carboxyl group of the now-exposed prenylated cysteine residue is subject to methylation. This reaction is catalysed by a specific protein methyltransferase which is also apparently localized to the microsomal membrane fraction in cells [26, 27] . Interestingly, in the cases of both the protease and the methyltransferase, a single form of each enzyme is apparently responsible for the processing of both farnesylated and geranylgeranylated proteins [28] . This suggests that both types of prenylated CaaX proteins (farnesylated and geranylgeranylated) share a common processing pathway once they have been modified by their respective protein prenyltransferase (see Figure 1 ).
In addition to proteins containing the CaaX motif, prenylation also occurs on a distinct class of monomeric G proteins termed Rab proteins [29] . These proteins play crucial roles in intracellular membrane trafficking [ 301, and most contain two cysteine residues at or near their C-termini. Prenylation of this class of proteins is catalysed by an enzyme designated protein geranylgeranyltransferase type I1 (GGTase-11) [31] . The 
Prenylation and heterotrimeric G proteins
In addition to Ras and related monomeric G proteins, prenylation also occurs on the class of heterotrimeric G proteins. These G proteins, comprising The influence of prenylation of G, localization and function has been addressed using a variety of approaches. Mutation of the relevant cysteine residue of G, subunits to serine produces proteins which are not prenylated and remain cytosolic (40,411. Co-expression of G, and G, by baculovirus infection of Sf9 cells has shown that, even with a G, subunit containing the Cys-to-Ser mutation which blocks processing, the expressed G, is still able to form a complex with G,. However, this G,, complex containing unprocessed G, was unable to function in interactions with either G, subunits or with a form of adenylate cyclase which is subject to regulation by G,, [42] .
Recently developed experimental systems for both in vitro processing of G, polypeptides and their assembly into G,, dimers have allowed investigation of the consequences of G, processing without the use of mutant proteins [43] . The three processing intermediates (unmodified, prenylated and truncated-prenylated) for two G, subunits, one of which is subject to farnesylation (G,,) and one of which is geranylgeranylated (Gy2), were produced. Assessment of the functional consequences of the processing of G, was found to require reconstitution of the polypeptide with a G protein /3 subunit.
Both prenylated and unprenylated G, subunits could form stable complexes with G, but, surprisingly, neither of the truncated-prenylated G, subunits (i.e. those missing the -aaX residues) were competent for this assembly. Furthermore, only those G,, complexes containing a prenylated G, subunit were competent to interact with a G, subunit. These results have confirmed that prenylation of G, is not required for G,, assembly, and that G,, complexes require prenylated G, for interaction with G,. Additionally, the data indicate that assembly of the G,, complex occurs before proteolytic processing of the prenylated G,,.
Role of the isoprenoid in prenyl protein membrane targeting
Another important question in this field is the role that prenylation plays in targeting many proteins to specific cellular membranes. While Ras and most heterotrimeric G proteins are specifically localized to the plasma membrane, other prenylated proteins are predominantly localized on intracellular membranes [ 1,2]. Since these differences in localization cannot be accounted for by distinct isoprenoids, additional determinants must be involved. Also, as noted above, studies showing that both the protease and methyltransferase involved in the processing of prenylated proteins recognize both farnesylated and geranylgeranylated proteins suggest that both classes of prenylated proteins share a common processing pathway after isoprenoid addition.
Through the use of radiolabelled, prenylated peptides as ligands, a specific, high-affinity binding activity on microsomal membranes has been identified [44] . This activity is both protease-and heatsensitive and exhibits high-affinity saturable binding of the prenylated peptide, indicating the presence of a binding protein or receptor. Competition analysis indicated that both geranylgeranylated and farnesylated, but not myristoylated, peptides bind to this receptor. A fully processed prenylated protein, however, did not compete, indicating that the receptor requires the three C-terminal amino acids (i.e. the 'aaX) for high-affinity recognition. A potential role for this receptor is as a 'docking site' to direct newly prenylated proteins to a microsomal compartment for completion of processing, which would occur prior to their trafficking to a final destination in the cell.
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Interaction of prenylcysteines with the developed drug resistance. Cells exhibiting multidrug resistance have increased expression of P-glycoprotein that coincides with a decreased intracellular accumulation of drugs; these findings led to the discovery that P-glycoprotein functions as an ATP-dependent drug efflux pump which reduces the intracellular accumulation of the drugs.
A potential link between P-glycoprotein and prenylated proteins has been revealed by studies using the yeast Saccharomyces cerevisiae [ 451. This organism uses a P-glycoprotein-like transporter, termed Ste6, for the export of the prenylated peptide mating pheromone, a-factor. In a yeast strain which lacks ste6 due to disruption of its gene, expression of mammalian P-glycoprotein complements the function of Ste6 and partially restores mating activity. These experiments suggested that the similarity between the mammalian P-glycoprotein transporter and Ste6 extends to function as well as structure. A further implication is that the structural domain(s) of the a-factor peptide which determines specific transport by Ste6 is also involved in its interaction with P-glycoprotein. Mature a-factor is a dodecapeptide containing a farnesylated C-terminus [46] . The discovery that P-glycoprotein expressed in yeast is capable of transporting this prenylated peptide raises an interesting question as to its involvement in exporting some derivative of prenylated proteins. Specifically, prenylated proteins comprise up to 2% of total cellular proteins [47] , and a potential metabolic problem for the cell which has yet to be addressed is the degradation of these proteins. Since prenylation is a stable modification of proteins [5] , their proteolytic degradation would generate the lipidmodified amino acids, farnesyl-and geranylgeranylcysteines. Accumulation of these compounds in cells could result in critical problems, since prenylated cysteines are known inhibitors of cellular processes such as protein methylation and signal transduction [48, 49] .
We have found that specific prenylcysteinecontaining compounds which represent the C-terminal structures of prenylated proteins can bind to P-glycoprotein and both stimulate its ATP activity and compete for drug binding [SO] . Recognition of prenylcysteines by P-glycoprotein required methylation of the a-carboxyl group of the Both farnesyl-and geranylgeranyl-cysteine methyl esters (FCME and GGCME respectively) modulate the ATPase activity of the transporter in a fashon similar to that of the well-studied drug, verapamil, while their unrnethylated counterparts, FC and GGC, are essentially without effect Adapted from [50] . molecules ( Figure 2) ; this is the form of the prenylcysteine that exists at the C-terminus of prenylated proteins. These results indicate that recognition of prenylcysteine-containing compounds is not a property limited to the yeast Ste6 transporter, which also recognizes the methylated form of its substrate [51] , and point to a potential physiological role for P-glycoprotein in the export of prenylated compounds which could be produced during prenyl protein turnover.
Conclusions
A clear link between prenylation and both membrane targeting and biological activity of many key signalling proteins has been established. Assessment of the functional consequences of prenylation and related modifications on the assembly and activity of G proteins and elucidation of the mechanisms of prenyl protein trafficking should continue to contribute to our detailed understanding of the biological properties of this processing. Future studies will undoubtedly provide new insight into the importance of prenylation in signalling pathways controlled by G proteins, and furnish data crucial to the analysis of studies evaluating the potential of using compounds directed at, or Volume 
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derived from, prenylated proteins as therapeutic agents.
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